Global Markets
S&P 500 — US Large Cap Index
NASDAQ 100 — Tech Growth Index
Dow Jones — Industrial Average
FTSE 100 — UK Blue Chips
Euro Stoxx 50 — Eurozone Leaders
DAX 40 — German Equities
CAC 40 — French Market Index
Nikkei 225 — Japan Benchmark
Hang Seng — Hong Kong Index
Shanghai Composite — China Mainland
ASX 200 — Australian Market
TSX Composite — Canada Index
Nifty 50 — India Large Cap
STI Index — Singapore Market
KOSPI — South Korea Index
Bovespa — Brazil Equities
JSE Top 40 — South Africa Index
IPC Index — Mexico Market
S&P 500 — US Large Cap Index
NASDAQ 100 — Tech Growth Index
Dow Jones — Industrial Average
FTSE 100 — UK Blue Chips
Euro Stoxx 50 — Eurozone Leaders
DAX 40 — German Equities
CAC 40 — French Market Index
Nikkei 225 — Japan Benchmark
Hang Seng — Hong Kong Index
Shanghai Composite — China Mainland
ASX 200 — Australian Market
TSX Composite — Canada Index
Nifty 50 — India Large Cap
STI Index — Singapore Market
KOSPI — South Korea Index
Bovespa — Brazil Equities
JSE Top 40 — South Africa Index
IPC Index — Mexico Market
AED • EUR • GBP • USD IBANs   |   CROSS BORDER FX   |   LOCAL CURRENCIES   |   GLOBAL COVERAGE
Economics and FinanceFinancial AnalysisGeo-PoliticalInternational RelationsMarketsOpinionStocksTechnical AnalysisWall Street

Costly war and lucrative contracts – Rebuilding ammo stocks after the Iran War

Markets are currently focusing more on the losses resulting from the ongoing conflict in the Persian Gulf. This instinct is entirely understandable, wars, ultimately, are costly negative-sum undertakings. Investors must price in losses to budgets, risks to growth, inflation, etc. The market participants that can generally only benefit from such a major escalation of tensions are defense companies. This time is no different. The U.S. and Israeli campaign in Iran remains, for now, primarily an air campaign. According to official data, the U.S. conducted, up to the ceasefire, more than 10,000 combat missions and struck over 13,000 targets in Iran. Ammunition is currently one of the most important bottlenecks in the defense industry, and the U.S. is no exception. According to analyses by, among others, CNN and CSIS, during Operation “Epic Fury” the U.S. used in Iran:

  • more than 1,000 BGM-109 “Tomahawk” missiles,
  • more than 1,000 “JASSM” missiles,
  • approx. 60 “PrSM” missiles,
  • nearly 250 SM-3 missiles,
  • more than 200 SM-6 missiles,
  • more than 200 “THAAD” interceptors,
  • more than 1,000 PAC-3 “Patriot” missiles.

This means that among the most advanced types of munitions, mainly long-range systems, the U.S. has now depleted roughly 30–60% of its pre-war stockpiles. However, this is not the Pentagon’s biggest problem. The problem is that these munitions are not only extremely expensive, but their production is also limited to only a few dozen units per year. With current production capacity, the U.S. will need roughly four years to rebuild stockpiles. This in no way means the U.S. is becoming “defenseless” or even ineffective. Nor does it mean a renewed escalation in Iran is unlikely. It does, however, highlight significant challenges for the Department of Defense and enormous opportunities for weapons suppliers to U.S. forces. Who are we talking about? Among producers of the most advanced U.S. munitions, RTX Corp. and Lockheed Martin maintain near-total dominance.

  • Tomahawk, SM-3, and SM-6 are products of RTX Corp.
  • JASSM, PrSM, THAAD, and PAC-3 Patriot are associated with Lockheed Martin.

Considering only stockpile replenishment, and based on publicly available data on prices and past orders – this implies amounts of roughly $20–30 billion over aprox. four years. Assuming a conservative $25 billion, that would translate into sales revenue of roughly $11–13 billion for RTX and roughly $13–16 billion for Lockheed Martin.

Using segment margins at these companies (12–13%), this implies operating profit of about $1.5–2.5 billion over the next four years, i.e., about $0.4–0.6 billion per year. A high degree of caution is warranted regarding the timing of these revenues. While production of the listed munitions is currently one of the Pentagon’s most pressing bottlenecks, major investments are underway intended – at least partially, to accelerate output.

The key question to answer is: is this already in the price?

Nothing suggests it is. Both companies appear to have performed weakly in recent quarters (given the context), and the trend worsened after the latest results. Because, based on forecasts for, among other things, the operating profit of both companies, it does not appear to have changed materially recently.

  • For Lockheed, expectations for 2026 and 2027 are $9.6 billion and $10.1 billion, respectively.
  • For RTX, expectations are $12.3 billion and $13.5 billion for 2025/2026.

If so, this implies a potential upside surprise of about $0.4–0.6 billion (~5%) in operating profit—an upside that the market does not currently see—at a time when both stocks are at multi-month lows.

Final remarks

Naturally, forecasts of this kind are not “absolute.” Neither RTX nor Lockheed is a company focused solely (or even primarily) on munitions—earnings forecasts can be diluted by the performance of other segments. Moreover, there is no high precision in estimating expenditures of this type. The specifics of producing these missiles are highly classified, margins are averaged, and many operational issues can appear or disappear unexpectedly without investors or the public being informed.

Register a Revolut Business Account
```

Market Analysis & Disclaimer

The market information, analysis, commentary, forecasts and opinions contained in this publication are provided by Octalas Group Ltd on behalf of Today Markets and Currency Hedger using information and data obtained from sources believed to be reliable. However, Octalas Group Ltd, Today Markets and Currency Hedger do not warrant or guarantee the accuracy, completeness or timeliness of the information presented and accept no responsibility for any loss or damage arising from reliance upon information contained herein, to the extent permitted by applicable law.

Market forecasts, expectations and opinions are based on analysis of available information and a number of assumptions regarding economic, financial, political and market conditions. Such assumptions may prove to be incorrect, and actual market developments may differ materially from those described or anticipated.

Nothing contained in this publication constitutes investment advice, financial advice, a personal recommendation, an offer, solicitation or invitation to buy, sell or otherwise transact in any financial instrument or investment product. The information is provided for general informational and educational purposes only and does not take into account the investment objectives, financial situation, experience or particular circumstances of any individual reader.

Past performance is not indicative of future results. Financial markets, including foreign exchange, commodities, equities, derivatives and other financial instruments, involve risk and prices can move rapidly. Readers should conduct their own independent research and, where appropriate, obtain advice from an appropriately authorised financial professional before making any investment or trading decision.

Where this publication refers to Today Markets, it represents market news, research, analysis and commentary published for informational purposes. Where Currency Hedger is referenced, it represents commentary concerning foreign exchange, currency exposure, international payments and hedging-related topics. References to particular financial instruments, markets, companies, currencies or commodities should not be interpreted as a recommendation to transact in them.

Octalas Group Ltd, Today Markets and Currency Hedger may have commercial interests or relationships with businesses, financial-service providers, technology providers or other market participants mentioned in their publications. Where relevant, such relationships or interests may create potential conflicts of interest. Appropriate measures are intended to be taken to ensure that published analysis and commentary are presented objectively and that commercial considerations do not determine the substance of market analysis.

The views expressed in this publication are those of the author or contributors at the time of publication and may change without notice as market conditions develop. Readers should not assume that any information contained herein has been updated following publication.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button